Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) – Pipeline Review, H1 2017’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST)

The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects

The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

Advanced Accelerator Applications SA

Advenchen Laboratories LLC

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

ArQule Inc

Array BioPharma Inc

Astex Pharmaceuticals Inc

Blueprint Medicines Corp

Boston Biomedical Inc

Calithera Biosciences Inc

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

CytRx Corp

Deciphera Pharmaceuticals LLC

Exelixis Inc

F. Hoffmann-La Roche Ltd

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immunicum AB

Jiangsu Hengrui Medicine Co Ltd

Natco Pharma Ltd

Nerviano Medical Sciences Srl

Novartis AG

Omeros Corp

Pharma Mar SA

Plexxikon Inc

Rhizen Pharmaceuticals SA

Taiho Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Gastrointestinal Stromal Tumor (GIST) - Overview 8

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development 27

AB Science SA 27

Advanced Accelerator Applications SA 27

Advenchen Laboratories LLC 28

Ariad Pharmaceuticals Inc 28

Arog Pharmaceuticals Inc 29

ArQule Inc 29

Array BioPharma Inc 30

Astex Pharmaceuticals Inc 30

Blueprint Medicines Corp 31

Boston Biomedical Inc 31

Calithera Biosciences Inc 32

Celldex Therapeutics Inc 32

Chipscreen Biosciences Ltd 33

CytRx Corp 33

Deciphera Pharmaceuticals LLC 34

Exelixis Inc 34

F. Hoffmann-La Roche Ltd 35

Hanmi Pharmaceuticals Co Ltd 35

Horizon Pharma Plc 36

Immunicum AB 36

Jiangsu Hengrui Medicine Co Ltd 37

Natco Pharma Ltd 37

Nerviano Medical Sciences Srl 38

Novartis AG 38

Omeros Corp 39

Pharma Mar SA 39

Plexxikon Inc 40

Rhizen Pharmaceuticals SA 40

Taiho Pharmaceutical Co Ltd 41

Gastrointestinal Stromal Tumor (GIST) - Drug Profiles 42

aldoxorubicin hydrochloride - Drug Profile 42

amcasertib - Drug Profile 59

apatinib - Drug Profile 62

ARQ-092 - Drug Profile 67

binimetinib - Drug Profile 70

BLU-285 - Drug Profile 79

buparlisib hydrochloride - Drug Profile 83

cabozantinib s-malate - Drug Profile 89

CB-839 - Drug Profile 108

CDX-0158 - Drug Profile 116

CHMFLKIT-110 - Drug Profile 119

crenolanib besylate - Drug Profile 120

CS-2164 - Drug Profile 124

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 125

DCC-2618 - Drug Profile 133

everolimus - Drug Profile 135

HM-95573 - Drug Profile 147

interferon gamma-1b - Drug Profile 149

Intuvax - Drug Profile 154

masitinib - Drug Profile 160

nilotinib - Drug Profile 176

NMSP-088 - Drug Profile 182

NRCAN-019 - Drug Profile 183

onalespib - Drug Profile 185

Peptide to Antagonize GRPR for Oncology - Drug Profile 189

pexidartinib - Drug Profile 190

PLX-9486 - Drug Profile 195

PM-184 - Drug Profile 196

ponatinib hydrochloride - Drug Profile 198

SF-1126 - Drug Profile 214

SHR-1020 - Drug Profile 216

Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile 218

Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile 219

TAS-116 - Drug Profile 220

TGR-1202 - Drug Profile 221

vemurafenib - Drug Profile 230

WBZ-4 - Drug Profile 237

Gastrointestinal Stromal Tumor (GIST) - Dormant Projects 238

Gastrointestinal Stromal Tumor (GIST) - Discontinued Products 239

Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones 240

Featured News & Press Releases 240

Appendix 255

Methodology 255

Coverage 255

Secondary Research 255

Primary Research 255

Expert Panel Validation 255

Contact Us 255

Disclaimer 256

List of Tables

List of Tables

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by AB Science SA, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advanced Accelerator Applications SA, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Advenchen Laboratories LLC, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Ariad Pharmaceuticals Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Arog Pharmaceuticals Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by ArQule Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Array BioPharma Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Blueprint Medicines Corp, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Boston Biomedical Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Calithera Biosciences Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Celldex Therapeutics Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by CytRx Corp, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Exelixis Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Horizon Pharma Plc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Immunicum AB, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Natco Pharma Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Nerviano Medical Sciences Srl, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Novartis AG, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Omeros Corp, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Pharma Mar SA, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Plexxikon Inc, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Rhizen Pharmaceuticals SA, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Dormant Projects, H1 2017

Gastrointestinal Stromal Tumor (GIST) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports